Very unlikely but report seizures, mood/mental changes, eye problems, unusual change in amount of urine, fever, rash, muscle/joint pain, trouble breathing, yellowing eyes/skin, unusual bleeding/bruising or chest pain/irregular heartbeat.

Watch the latest videos on YouTube.com

Precautions:

Before taking this drug, tell your doctor your entire medical history, especially including any allergies, previous drug reactions (rash) to sunlight, kidney disease, heart conditions, certain mental conditions (psychosis), blood vessel disease (carotid arteries), brain disorders (e.g., seizures or or cancer) or tendon problems.

This drug is not used in people who must be exposed to sunlight as part of job or lifestyle.

Exposure to direct or indirect sunlight, tanning lamps, etc., should be avoided for the entire treatment period and five days beyond.

Only sunscreens which block UV-A rays (e.g., octocrylene or Parsol-1789 containing products) have been effective protection, along with adequate clothing.

Limit alcohol, since this drug could cause drowsiness and alcohol can intensify this effect.

Caution performing tasks requiring mental alertness until you know the effect of the drug.

This medication should be used only when clearly needed during pregnancy.

Discuss the risks and benefits with your doctor.

This drug is excreted into human milk.

It is advised to either stop the drug or stop breast-feeding.

Consult your doctor before breast-feeding.

This antibiotic is not recommended for use in persons under 18 years old.

Use of this medication for prolonged or repeated periods may result in a secondary infection (e.g., oral, bladder or vaginal yeast infection) .

Related Drugs:

Zagam 200 mg Tablet - Prescription

Sparfloxacin

20677slr006_zagam_lbl.pdf

http://www.fda.gov/cder/foi/label/2003/20677slr006_zagam_lbl.pdf

sparfloxacin, susceptibility, pneumoniae, dose, administration, strains, Haemophilus influenzae, patients, blood, Haemophilus parainfluenzae, standard, pharmacokinetics, quinolones.

Rx only DESCRIPTION: Zagam® (sparfloxacin) tablets contain sparfloxacin, a synthetic broad-spectrum antimicrobial agent for oral administration.
Maximum plasma concentrations for a 200-mg dose were also achieved between 3 to 6 hours after administration with a mean of about 4 hours.
INDICATIONS AND USAGE: Zagam (sparfloxacin) is indicated for the treatment of adults (18 years of age) with the following infections caused by susceptible strains of the designated microorganisms: Community-acquired pneumonia caused by Chlamydia pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, or Streptococcus pneumoniae Acute bacterial exacerbations of chronic bronchitis caused by Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, or Streptococcus pneumoniae Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to sparfloxacin.

1955.pdf

Facts, comparaisons, Missouri, St-Louis, Drug Interaction Facts, Hebel, Olin, Tatro, Promazine, RefID, cardiac arrest, pointes, torsades.

Increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Tatro DS, Olin BR, Hebel SK et al. Drug Interaction Facts, St-Louis, Missouri: Facts and comparaisons, 2002.

BoyakaCV.pdf

Cormet-Boyaka, CFTR, Kirk, Cystic Fibrosis, Physiology, Tome, J-F Huneau, Caco-2, sparfloxacin, Annual North American, syntaxin, Carbon, Rubinstein.

University of Pharmacy, Paris XI, Chatenay- Malabry, France.
INRA-INA-PG, Paris, France Mechanism of transport of antibiotics in intestinal epithelial cells.
French Ministry of Research and Education pre-doctoral fellowship in: 1993-94; 1994-95 and 1995-96.
Member of The American Physiological Society (since 2003).
Evidence for a passive diffusion of sparfloxacin through the brush-border membrane of Caco-2 cells.
Syntaxin 1A is expressed in native airway epithelial tissues where it tonically inhibits CFTR function.
CFTR chloride channel regulation by an interdomain interaction.
CECED (Club d'Etude des Cellules Epitheliales et Digestives), Toulouse, France, November 1995.
Thirteenth Annual North American Cystic Fibrosis Conference, Seattle, Washington, October 7-10, 1999.